📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
Torrent Pharma Shareholders Approve Merger with J.B. Chemicals & Pharmaceuticals
Shareholders of Torrent Pharmaceuticals have officially approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited in an NCLT-convened meeting held on April 28, 2026. The resolution was passed with the requisite majority, satisfying the requirement of a majority in number and three-fourths in value of the shareholders who cast their votes. This approval is a critical milestone in the merger process, which aims to consolidate the operations of both pharmaceutical entities. The company will now proceed with the remaining regulatory steps to finalize the transaction.
Key Highlights
Shareholders approved the merger of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited.
The resolution passed with a majority in number and 75% in value of the equity shareholders who voted.
The NCLT-convened meeting was conducted via video conferencing on April 28, 2026, concluding in 21 minutes.
Compliance with Section 230(6) of the Companies Act, 2013, has been achieved for this shareholder vote.
👀 What to Watch
Investors should view this as a positive step toward scale and synergy; monitor the final NCLT approval and the subsequent integration process for long-term value creation.
Torrent Pharma's Bileshwarpura Oncology Unit Gets Zero USFDA Observations
Torrent Pharmaceuticals has successfully cleared a USFDA inspection at its Bileshwarpura oncology facility. The audit, which took place from April 6 to April 10, 2026, concluded with zero observations. This clean report indicates that the facility meets the stringent quality standards required for the US market. Such regulatory clearances are vital for maintaining existing product sales and securing approvals for new drug applications in the oncology segment.
Key Highlights
USFDA inspection of the Bileshwarpura (Oncology) facility concluded on April 10, 2026.
The audit resulted in zero observations, meaning no Form 483 was issued by the regulator.
The inspection spanned five days, starting from April 6, 2026.
Successful compliance strengthens the company's position and growth prospects in the US oncology market.
👀 What to Watch
The zero-observation status is a strong positive signal for the company's manufacturing quality and reduces regulatory risk. Investors should view this as a positive development for the company's US-bound oncology pipeline.
Torrent Pharma to Hold Shareholder Meeting on April 28 for J.B. Chemicals Merger
Torrent Pharmaceuticals has scheduled a court-convened meeting on April 28, 2026, to seek shareholder approval for the merger of J.B. Chemicals & Pharmaceuticals Limited into the company. This follows a National Company Law Tribunal (NCLT) order dated March 23, 2026, marking a significant step in the consolidation process. The merger is supported by fairness opinions from Axis Capital and ICICI Securities and a joint valuation report from E&Y and BDO. This strategic move aims to strengthen Torrent's market position through the integration of J.B. Chemicals' portfolio.
Key Highlights
Court-convened meeting for equity shareholders scheduled for April 28, 2026, at 10:00 a.m. IST.
Remote e-voting period set from April 24, 2026, to April 27, 2026, with a cut-off date of April 21, 2026.
The scheme involves the complete amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals.
Fairness opinions and valuation reports were finalized in June 2025, with SEBI observation letters received in February 2026.
The merger is being conducted under Sections 230 to 232 of the Companies Act, 2013.
👀 What to Watch
Investors should review the scheme of amalgamation and participate in the voting process, as this merger is a major growth driver for the company. Monitor the subsequent NCLT final approval and integration timelines for potential synergy benefits.
Torrent Pharma Sets April 28 Meeting for Shareholder Approval of J.B. Chemicals Merger
Torrent Pharmaceuticals has scheduled a court-convened meeting on April 28, 2026, to seek shareholder approval for the merger of J.B. Chemicals & Pharmaceuticals Limited into the company. The merger process follows an NCLT order dated March 23, 2026, and previous observation letters from BSE and NSE received in February 2026. Shareholders as of the cut-off date of April 21, 2026, are eligible to vote on the resolution. This consolidation is a major strategic move aimed at expanding Torrent's market share and therapeutic reach in the pharmaceutical sector.
Key Highlights
Court-convened meeting scheduled for April 28, 2026, to approve the Scheme of Amalgamation.
Cut-off date for voting eligibility is April 21, 2026, with remote e-voting from April 24 to April 27.
BSE and NSE issued observation letters for the merger on February 17, 2026.
Joint Share Exchange Ratio Report and Fairness Opinions were finalized on June 29, 2025.
The merger involves J.B. Chemicals & Pharmaceuticals Limited as the Transferor Company.
👀 What to Watch
Investors should review the share exchange ratio and merger documents to understand the long-term synergy benefits. Participation in the e-voting process is recommended to support this significant corporate consolidation.
Torrent Pharma Receives NCLT Corrigendum Order for J.B. Chemicals Amalgamation
Torrent Pharmaceuticals has received a corrigendum order from the NCLT Ahmedabad Bench regarding its proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. This follows the initial order dated March 24, 2026, and represents a procedural legal step in the merger process. The amalgamation aims to consolidate the operations of J.B. Chemicals into Torrent Pharma to drive synergies. The official order was uploaded to the NCLT website on March 25, 2026, for public record.
Key Highlights
NCLT Ahmedabad Bench issued a Corrigendum Order on March 24, 2026, regarding the merger.
The order pertains to the Scheme of Amalgamation between J.B. Chemicals & Pharmaceuticals and Torrent Pharma.
The document was officially uploaded to the NCLT website on March 25, 2026.
This update follows the company's previous regulatory intimation dated March 24, 2026.
👀 What to Watch
Investors should monitor the final approval timelines and integration plans as the merger could significantly impact market share and operational efficiency. No immediate portfolio changes are required based on this procedural update.
Torrent Pharma Receives NCLT First Motion Order for J.B. Chemicals Amalgamation
Torrent Pharmaceuticals has achieved a procedural milestone in its proposed merger with J.B. Chemicals & Pharmaceuticals Limited. The Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, uploaded the order for the first motion application on March 23, 2026. This development follows the initial amalgamation announcement made on June 29, 2025. The merger is expected to consolidate the market position of Torrent Pharma once all regulatory approvals are finalized.
Key Highlights
NCLT Ahmedabad Bench uploaded the first motion order on March 23, 2026.
The scheme involves the amalgamation of J.B. Chemicals & Pharmaceuticals into Torrent Pharmaceuticals.
The merger process was originally initiated and disclosed to exchanges on June 29, 2025.
This legal step indicates steady progress in the regulatory approval timeline for the M&A activity.
👀 What to Watch
Investors should view this as a positive step toward the completion of a significant acquisition. Monitor for subsequent NCLT hearings and the final order to assess the impact on the company's consolidated financials.
Torrent Pharma Launches Generic Semaglutide (Oral & Injectable) Starting at Rs 3,999/Month
Torrent Pharmaceuticals has entered the high-growth GLP-1 therapy segment by launching generic Semaglutide under the brands Sembolic and Semalix. It is the first Indian company to offer generic oral formulations, alongside an injectable version priced competitively at Rs 3,999 per month. This move targets the massive Type-2 diabetes and obesity market in India, leveraging Torrent's 5th rank in the Indian Pharma Market. With approximately 76% of its domestic revenue derived from chronic therapies, this launch significantly strengthens its core portfolio.
Key Highlights
First Indian company to launch generic oral semaglutide formulations in the domestic market.
Injectable semaglutide launched with a competitive starting price of Rs 3,999 per month.
Targets the metabolic disorder segment, addressing Type-2 diabetes and obesity management.
Strengthens Torrent's chronic therapy portfolio, which accounts for ~76% of its India revenues.
Torrent Pharma maintains a strong market position with annual revenues exceeding Rs 11,500 crores.
👀 What to Watch
Investors should monitor the adoption rate of these generic formulations as they disrupt a high-value therapeutic segment. This launch is a significant growth catalyst for Torrent's domestic chronic business.
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a strong performance for Q3 FY2025-26, with net profit increasing 19% year-on-year to ₹577 crores. Revenue from operations grew to ₹2,599 crores compared to ₹2,377 crores in the same quarter last year. The company's board declared a substantial interim dividend of ₹29 per share (580% of face value), with a payout expected by March 6, 2026. For the nine-month period, the company has shown consistent growth, with total profit reaching ₹1,725 crores against ₹1,414 crores in the previous year.
Key Highlights
Net profit for Q3 FY26 rose 19% YoY to ₹577 crores from ₹485 crores.
Revenue from operations increased to ₹2,599 crores, up from ₹2,377 crores in Q3 FY25.
Declared an interim dividend of ₹29 per equity share (580% of face value).
Earnings Per Share (EPS) for the quarter improved to ₹17.04 from ₹14.33 YoY.
Nine-month total income grew to ₹7,937 crores compared to ₹7,266 crores in the prior year period.
👀 What to Watch
Investors should consider the strong bottom-line growth and healthy dividend payout as positive indicators of operational efficiency. The stock remains a robust pick for those seeking a combination of growth and regular income.
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a strong performance for Q3 FY26, with revenue from operations growing to ₹2,599 crore compared to ₹2,377 crore in the same quarter last year. Net profit saw a significant jump of approximately 19% year-on-year, reaching ₹577 crore. The company also announced a substantial interim dividend of ₹29 per equity share, representing 580% of the face value. For the nine-month period ended December 2025, the company maintained momentum with a net profit of ₹1,725 crore against ₹1,414 crore in the previous year.
Key Highlights
Revenue from operations increased by 9.3% YoY to ₹2,599 crore in Q3 FY26
Net profit for the quarter grew by 19% YoY to ₹577 crore from ₹485 crore
Board declared an interim dividend of ₹29 per share (580%) with payment expected by March 6, 2026
Basic and Diluted EPS improved to ₹17.04 for the quarter compared to ₹14.33 in the previous year's quarter
9M FY26 net profit stands at ₹1,725 crore, showing a robust 22% growth over 9M FY25
👀 What to Watch
Investors should view the consistent double-digit profit growth and high dividend payout as a sign of strong operational health. The stock remains a solid hold for long-term investors looking for steady earnings growth and dividend income.
Torrent Pharma Q3 FY26 Revenue Grows 18% YoY to Rs 3,303 Crore
Torrent Pharmaceuticals reported a strong 18% year-on-year growth in total revenue for Q3 FY26, reaching Rs 3,303 crore compared to Rs 2,809 crore in the previous year. The growth was broad-based across all geographies, with the Brazil market leading at 27% growth and the US market growing by 19%. The core India business, which remains the largest contributor, grew by 14% to Rs 1,798 crore. For the nine-month period ending December 2025, the company achieved a total revenue of Rs 9,783 crore, marking a 14% increase over the same period last year.
Key Highlights
Total Q3 FY26 revenue increased 18% YoY to Rs 3,303 crore from Rs 2,809 crore
Brazil business recorded the highest regional growth of 27% YoY, reaching Rs 371 crore
India domestic revenue grew 14% YoY to Rs 1,798 crore, maintaining its dominant share
US revenue saw a significant 19% YoY increase to Rs 321 crore
YTD Dec 25 total revenue stands at Rs 9,783 crore, up 14% from Rs 8,557 crore in YTD Dec 24
👀 What to Watch
Investors should take note of the robust double-digit growth across all major markets, indicating strong operational momentum. The stock remains a key pick in the pharma sector due to its high domestic exposure and improving international performance.
Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr
Torrent Pharmaceuticals has declared an interim dividend of ₹29 per share (580% of face value) for FY 2025-26. The company reported a strong Q3 FY26 performance with net profit rising 19% year-on-year to ₹577 crores, up from ₹485 crores in the same quarter last year. Revenue for the quarter grew to ₹2,599 crores, reflecting steady operational growth. The dividend is expected to be paid to shareholders on or around March 6, 2026.
Key Highlights
Declared an interim dividend of ₹29 per equity share of ₹5 face value
Q3 FY26 Net Profit grew 19% YoY to ₹577 crores vs ₹485 crores in Q3 FY25
Total Revenue from operations for Q3 FY26 rose to ₹2,599 crores from ₹2,377 crores YoY
Nine-month (9M FY26) Net Profit reached ₹1,725 crores compared to ₹1,414 crores in 9M FY25
Dividend payment is scheduled to be dispatched on or around March 6, 2026
👀 What to Watch
Investors should consider the healthy dividend payout and double-digit profit growth as a sign of strong cash flow and operational stability. The stock remains a solid pick for long-term portfolios seeking a mix of growth and regular income.
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a solid performance for Q3 FY26, with revenue from operations growing 9.3% year-on-year to ₹2,599 crore. Net profit saw a significant jump of 19%, reaching ₹577 crore compared to ₹485 crore in the same quarter last year. The board has rewarded shareholders with a substantial interim dividend of ₹29 per equity share. Despite a slight sequential dip in revenue compared to Q2 FY26, the year-to-date profit growth remains robust at 22%.
Key Highlights
Revenue from operations increased to ₹2,599 crore, up 9.3% YoY from ₹2,377 crore.
Net Profit for the quarter stood at ₹577 crore, representing a 19% YoY growth.
Interim dividend of ₹29 per share (580%) announced with a payment date around March 6, 2026.
Nine-month FY26 net profit reached ₹1,725 crore, a 22% increase over the previous year's ₹1,414 crore.
Basic EPS improved to ₹17.04 for the quarter from ₹14.33 in the year-ago period.
👀 What to Watch
Investors should find the strong double-digit profit growth and high dividend payout encouraging, reflecting healthy cash flows. The stock remains a solid pick for those seeking stability in the domestic-focused pharmaceutical space.
Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr
Torrent Pharmaceuticals has declared a substantial interim dividend of ₹29 per equity share (580% of face value) for the financial year 2025-26. The company reported a strong Q3 performance with standalone net profit rising 19% year-on-year to ₹577 crore, driven by a 9.3% growth in total revenue to ₹2,599 crore. For the nine-month period ended December 2025, the company's net profit saw a significant 22% increase to ₹1,725 crore. The dividend is expected to be paid to shareholders on or around March 6, 2026.
Key Highlights
Declared an interim dividend of ₹29 per equity share of ₹5 each (580% payout)
Standalone Q3 net profit increased by 19% YoY to ₹577 crore from ₹485 crore
Total revenue for Q3 FY26 grew to ₹2,599 crore compared to ₹2,377 crore in Q3 FY25
9-month standalone net profit reached ₹1,725 crore, up from ₹1,414 crore in the previous year
Dividend payment or dispatch is scheduled to be completed by March 6, 2026
👀 What to Watch
Investors should maintain a positive outlook given the strong 19% profit growth and healthy dividend payout. The stock remains attractive for long-term investors seeking consistent yield and steady earnings expansion in the pharmaceutical sector.
Torrent Pharma Completes JB Chemicals Stake Acquisition, Reaches 48.80% Holding
Torrent Pharmaceuticals has successfully completed its planned acquisition of J.B. Chemicals & Pharmaceuticals Limited shares. On February 3, 2026, the company acquired a final tranche of 92,490 shares (0.06%) from an employee, fulfilling all obligations under the Share Purchase Agreements dated June and July 2025. Following this transaction, Torrent Pharma's total stake in JB Chemicals stands at 48.80%, representing 7,83,57,892 equity shares. This marks the conclusion of a major strategic investment process initiated in 2025.
Key Highlights
Acquired 92,490 equity shares (0.06% stake) from a JB Chemicals employee on February 3, 2026
Total aggregate holding in JB Chemicals reached 7,83,57,892 equity shares
Final ownership stake stands at 48.80% of JB Chemicals on a fully diluted basis
Completion of all acquisitions under the Share Purchase Agreements dated June 29 and July 3, 2025
👀 What to Watch
Investors should view this as a significant strategic consolidation that strengthens Torrent's market position; focus on upcoming quarterly results to see the impact of JB Chemicals' integration on the consolidated bottom line.
Torrent Pharma Sets Feb 19, 2026, as Record Date for Interim Dividend
Torrent Pharmaceuticals has fixed February 19, 2026, as the record date to determine shareholder eligibility for a potential interim dividend. The formal declaration of this dividend is subject to approval at the Board of Directors meeting scheduled for February 13, 2026. This announcement pertains to equity shares with a face value of ₹5 each. Investors holding the stock on the record date will be entitled to the payout if approved.
Key Highlights
Record date for interim dividend eligibility is Thursday, February 19, 2026.
Board meeting to consider and declare the dividend is scheduled for February 13, 2026.
The dividend applies to equity shares with a face value of ₹5 per share.
The notification is issued under Regulation 42 of SEBI Listing Regulations.
👀 What to Watch
Investors seeking to receive the dividend should ensure they purchase or hold shares before the ex-dividend date. Monitor the February 13 board meeting outcome for the specific dividend amount per share.
Torrent Pharma's Dahej Facility Clears USFDA Inspection with Zero Observations
Torrent Pharmaceuticals has announced the successful conclusion of a USFDA inspection at its Dahej manufacturing facility. The audit took place from January 19 to January 23, 2026, and resulted in zero observations. This clean report signifies full compliance with global manufacturing standards and removes potential regulatory hurdles for the site. Such outcomes are critical for pharmaceutical companies to maintain and expand their product portfolio in the lucrative US market.
Key Highlights
USFDA inspection of the Dahej facility concluded on January 23, 2026
The audit resulted in zero observations, meaning no Form 483 was issued
Inspection period spanned five days from January 19 to January 23, 2026
Successful clearance ensures continued compliance for exports to the US market
👀 What to Watch
This is a significant positive development that de-risks the company's US-led growth strategy. Investors should maintain confidence in the company's manufacturing quality and regulatory standing.
Torrent Pharma's Dahej Facility Clears USFDA Inspection with Zero Observations
Torrent Pharmaceuticals has successfully completed a USFDA inspection at its Dahej manufacturing facility. The inspection, which took place from January 19 to January 23, 2026, concluded with zero observations. This clean report indicates full compliance with international manufacturing standards and removes potential regulatory bottlenecks for the US market. Such an outcome is highly favorable for the company's export growth and future product approvals.
Key Highlights
USFDA inspection conducted at the Dahej facility from 19-Jan-26 to 23-Jan-26.
The inspection concluded with zero observations, meaning no Form 483 was issued.
Successful audit ensures continued compliance for the company's US-bound exports.
The clean report de-risks the facility from potential import alerts or warning letters.
👀 What to Watch
This is a significant positive development that reduces regulatory risk; investors should maintain a positive outlook on the stock as it clears the path for new product launches in the US.
Torrent Pharma Completes Acquisition of 46.39% Stake in J.B. Chemicals
Torrent Pharmaceuticals has successfully completed the acquisition of a 46.39% stake in J.B. Chemicals & Pharmaceuticals Limited, totaling 7,44,82,836 equity shares. The acquisition was primarily executed through a share purchase agreement with Tau Investment Holdings Pte. Ltd. and supplemented by an open offer. Consequently, Torrent Pharma has assumed control of J.B. Chemicals and is now officially classified as its promoter effective January 21, 2026. This move marks a significant consolidation in the Indian pharmaceutical space, bringing a major domestic player under Torrent's umbrella.
Key Highlights
Acquired 7,44,81,519 shares (46.39% stake) from Tau Investment Holdings Pte. Ltd.
Total holding stands at 7,44,82,836 shares including 1,317 shares from the open offer.
Torrent Pharma is now the official 'promoter' of J.B. Chemicals as of January 21, 2026.
The transaction completes a process initiated via a share purchase agreement dated June 29, 2025.
👀 What to Watch
Investors should view this as a major strategic expansion that strengthens Torrent's domestic portfolio and market share. Monitor the upcoming consolidated financial statements to evaluate the synergy benefits and the impact of acquisition debt on the balance sheet.
Torrent Pharma Allots NCDs Worth INR 10,990 Crore Across Four Series
Torrent Pharmaceuticals has successfully allotted 10.99 lakh Non-Convertible Debentures (NCDs) to raise a total of INR 10,990 crore through private placement. The fundraise is structured into four series with tenures ranging from 2 to 5 years and coupon rates between 7.45% and 7.80% per annum. These are senior, secured instruments backed by specified trademarks and designated accounts with a 1.1x security cover. This significant capital infusion is likely intended for refinancing existing debt or funding strategic growth initiatives.
Key Highlights
Total allotment of 10,99,000 NCDs aggregating to INR 10,990 crore via private placement
Four series issued with coupon rates ranging from 7.45% for 2-year tenure to 7.80% for 5-year tenure
Instruments are secured by a first ranking exclusive charge on specified trademarks with a 1.1x cover
Redemption dates are staggered across January 2028, 2029, 2030, and 2031
Subscription amounts received for Series 4 reached INR 3,504.51 crore against a nominal value of INR 3,500 crore
👀 What to Watch
Investors should monitor the company's debt-to-equity ratio and the specific end-use of these funds, as such large-scale borrowing typically precedes major acquisitions or significant debt restructuring. The competitive interest rates obtained suggest strong institutional confidence in the company's credit profile.
Torrent Pharma Allots NCDs Worth ₹10,990 Crore Across Four Series
Torrent Pharmaceuticals has approved the allotment of Senior, Secured, Redeemable Non-Convertible Debentures (NCDs) totaling approximately ₹10,990 crore via private placement. The issuance is spread across four series with tenures ranging from 2 to 5 years and annual coupon rates between 7.45% and 7.80%. These securities are backed by a 1.1x security cover involving specified trademarks and designated accounts. This significant capital raise is likely aimed at refinancing existing debt or supporting large-scale strategic initiatives.
Key Highlights
Total fundraise of ₹10,990 crore through four distinct series of NCDs.
Coupon rates range from 7.45% for the 2-year series to 7.80% for the 5-year series.
Series 4 is the largest tranche, raising ₹3,500 crore with a maturity date of January 17, 2031.
The NCDs are secured by a first ranking exclusive charge over specified trademarks and designated accounts with 1.1x cover.
Allotment completed on January 19, 2026, with listing proposed on the NSE Wholesale Debt Market.
👀 What to Watch
Investors should monitor the company's upcoming quarterly calls for clarity on the specific utilization of these funds, particularly regarding potential M&A or debt restructuring. The competitive interest rates reflect the company's strong credit profile in the debt market.
